SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 105.71+3.6%3:16 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: George Sepetjian who wrote (598)5/11/1998 11:46:00 AM
From: George Sepetjian  Read Replies (1) of 3202
 
Another Downgrade-rush to judgment?



Genesis Downgrades Incyte to Hold from Strong Buy

May 11, 1998 11:25 AM

SAN FRANCISCO, May 11 /PRNewswire/ -- Genesis Merchant Group
Securities downgraded Incyte Pharmaceuticals, Inc. INCY to Hold from Strong
Buy.

Genesis analyst Deepa Pakianathan said, "A new company is being formed by
Perkin-Elmer and The Institute for Genome Research's Craig Venter to
sequence the human genome within the next three years. We believe this will
accelerate the devaluation of commercial databases like Incyte's because the
new company will make the information available to the scientific community."

"We expect that, as freely available human genome information becomes
available over the next three years, this will negatively impact Incyte's ability to
sign on new subscribers to LifeSeq and LifeSeqFL," added Pakianathan.
SOURCE Genesis Merchant Group Securities

Top

Terms of Use, and Privacy Policy. c 1996-98 Microsoft Corporation and/or its suppliers. All rights
reserved.

c 1998 PR Newswire. All rights reserved.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext